Skip to main content
Premium Trial:

Request an Annual Quote

PGDx, MolecularMD Ink Co-Marketing Deal

NEW YORK (GenomeWeb News) – Personal Genome Diagnostics today announced a deal with MolecularMD to market personalized medicine services to oncology researchers and drug developers.

The deal combines PGDx's expertise in next-generation sequencing-based cancer biomarker discovery with MolecularMD's capabilities in developing and validating cancer companion diagnostics, PGDx said. Under the agreement's terms, the two companies will co-market each other's services to drug manufacturers and biotechnology customers.

Further financial terms were not disclosed.

Baltimore-based PGDx provides genome mapping services and analyses to cancer researchers, clinicians, and patients. In the spring it announced a collaboration with BluePrint Medicines aimed at novel kinase targets for cancer drugs. The company licenses digital karyotyping technology from Johns Hopkins University that was developed by PGDx's founders.

MolecularMD, headquartered in Portland, Ore., provides molecular diagnostic products and services to the pharmaceutical and biotechnology sector.

"This collaboration will now enable the two companies to provide a complete spectrum of genomic services to drug developers," Antony Newton, chief commercial officer of PGDx, said in a statement.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.